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Organ ﬁbrosis is a pathological condition associated with chronic inﬂammatory diseases. In
ﬁbrosis, excessive deposition of extracellular matrix (ECM) severely impairs tissue architec-
ture and function, eventually resulting in organ failure.This process is mediated primarily by
the induction of myoﬁbroblasts, which produce large amounts of collagen I, the main com-
ponent of the ECM. Accordingly, the origin, developmental pathways, and mechanisms of
myoﬁbroblast regulation are attracting increasing attention as potential therapeutic targets.
The ﬁbrotic cascade, from initial epithelial damage to eventual myoﬁbroblast induction, is
mediated by complex biological processes such as macrophage inﬁltration, a shift from
Th1 toTh2 phenotype, and by inﬂammatory mediators such as transforming growth factor-
β. Here, we review the current understanding of the cellular and molecular mechanisms
underlying organ ﬁbrosis.
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INTRODUCTION
Organ ﬁbrosis is an intractable, progressive condition that arises
in multi-factorial chronic inﬂammatory diseases in which exces-
sive deposition of extracellular matrix (ECM), mainly composed
of collagen I (Col I), severely impairs tissue architecture and func-
tion, eventually resulting in organ failure (Kis et al., 2011). Fibrosis
affects various organs following tissue injury, including the lungs,
liver, and kidneys, and has become a major cause of death in the
developed world.
Lung ﬁbrosis occurs mainly in idiopathic interstitial pneumo-
nia (IIPs), a general term describing multi-factorial conditions
such as idiopathic pulmonary ﬁbrosis (IPF), non-speciﬁc intersti-
tial pneumonia (NSIP), and cryptogenic organizing pneumonia
(COP). IPF is a chronic and progressive disease with an estimated
prevalence of 20 cases per 100,000. The prognosis for patients with
IPF is poor, and 50% die within 3 years of diagnosis.
Hepatic ﬁbrosis (ﬁbrosis of the liver) can be triggered by the
hepatitis virus or alcohol. There are an estimated 350 million and
180million carriers of theHepatitis B (HBV) andC (HCV) viruses
worldwide, respectively. In Japan, deaths from hepatic cirrhosis
total around 15,000 per year (HCV, 50%; HBV, 12%; non B/non
C, 4%; alcoholic hepatitis, 13%). In addition, hepatic cirrhosis is
associated with hepatic cancer, which causes over 30,000 deaths
annually. The prevalence of non-alcoholic steatohepatitis (NASH)
Abbreviations: smooth muscle actin; Ang II, angiotensin II; BMP, bone mor-
phogenic protein; Col I, collagen I; CTGF, connective tissue growth factor; EMT,
epithelial–mesenchymal transition; FSP-1, ﬁbroblast speciﬁc protein-1; HBV/HCV,
hepatitis B/C virus; IIP, idiopathic interstitial pneumonia; IPF, idiopathic pul-
monary ﬁbrosis; LPA, lysophosphatidic acid; LT, leukotriene; MMP, matrix met-
alloproteinase; MSC,mesenchymal stem cell; PDGF, platelet-derived growth factor;
PGE2, prostaglandin E2; S1P, sphingosine-1-phosphate; TGFβ, transforming growth
factor-β; TIMP, tissue inhibitor of matrix metalloproteinases.
ranges from 9 to 37% of the population depending on the country,
and a subset of NASH patients eventually develops hepatitis and
hepatic cancer.
Kidney ﬁbrosis commonly occurs in glomerulonephritis and
diabetic nephropathy. While the number of patients requiring
dialysis due to chronic glomerulonephritis has decreased in recent
years, the number of those with diabetic nephropathy continues
to increase year by year. The cost of dialysis represents a consid-
erable medical expense in advanced countries. In addition, organ
ﬁbrosis is associated with autoimmune diseases. About 15–30% of
rheumatoid arthritis patients develop IPF, and about 30% of IIP
cases are associated with autoimmune diseases.
Given the prevalence and severity of diseases involving tissue
ﬁbrosis, the prevention, and treatment of this condition remains a
major medical challenge. This review focuses on the cellular and
molecular bases for the accumulation of Col I producing ﬁbrob-
lasts and myoﬁbroblasts, which are responsible for the excessive
deposition of ECM during the ﬁbrotic process.
THE ORIGIN OF Col I PRODUCING FIBROBLASTS AND
MYOFIBROBLASTS
Fibroblasts arenon-hematopoietic,non-epithelial,non-endothelial
cells that widely distribute throughout the mesenchyme where
they synthesize ECM proteins that form a structural framework
to support tissue architecture and function in steady-state con-
ditions. Fibroblasts also play an important role in tissue repair
following multi-factorial tissue damage by forming a provisional
ECM, a process preceding re-epithelialization in successful repair.
Unfortunately, dysregulated activation, proliferation, and sur-
vival of ﬁbroblasts often results in the excessive deposition of
ECM proteins and the inhibition of re-epithelialization, lead-
ing to tissue ﬁbrosis (Gabbiani, 2003). Therefore, control of the
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activation, proliferation, and survival of ﬁbroblasts is critical for
the prevention and treatment of tissue ﬁbrosis.
Fibroblasts form clusters within ﬁbrotic tissues that are known
as ﬁbrotic foci (Visscher and Myers, 2006). These ﬁbroblasts
includeα-smoothmuscle actin (αSMA) expressingmyoﬁbroblasts
that have the potential to produce large amounts of Col I, which
has resulted in this cell population being widely considered to be
the key effector cells in organ ﬁbrosis (Gabbiani et al., 1971; Gab-
biani, 2003; Sandbo and Dulin, 2011). Results in some models of
organ ﬁbrosis have suggested that theremay be therapeutic beneﬁt
in targetingmyoﬁbroblasts, although the experimental approaches
in these models leave-questions remaining about the selectivity of
the interventions for myoﬁbroblasts (Douglass et al., 2008). As
mentioned above, ﬁbroblasts are immunophenotypically identi-
ﬁed as cells negative for hematopoietic, epithelial, and endothelial
makers. The lack of speciﬁc markers for ﬁbroblasts or possible
subpopulations, includingmyoﬁbroblasts, complicates the cellular
and molecular understanding of these cells. Thus, the establish-
ment of speciﬁcmarkers to identify ﬁbroblasts andmyoﬁbroblasts
remains a major challenge in this ﬁeld.
Myoﬁbroblasts have classically been considered to differen-
tiate from tissue-resident ﬁbroblasts. However, recent studies
have suggested alternative sources of myoﬁbroblasts (Hinz et al.,
2007). Bone marrow-derived ﬁbrocytes express both hematopoi-
eticmarkers (CD45,CD11b, andHLADR) and ECMproteins (Col
I and vimentin). These cells have been shown to be recruited from
the circulation to inﬂamed tissues via chemokine receptorsCXCR4
and CCR1, 2, 5, and 7, after which they differentiate into myoﬁ-
broblasts (Phillips et al., 2004; Keeley et al., 2011). Epithelial cells
are reported to trans-differentiate into myoﬁbroblasts via chronic
inﬂammation-induced epithelial–mesenchymal transition (EMT)
in several ﬁbrosis models (Kalluri and Neilson, 2003). In addi-
tion, blood vessel wall smooth muscle cells have been proposed
as myoﬁbroblast progenitors. Meanwhile, stellate cells (Ito cells), a
type of hepatic pericyte, have attracted interest as a major precur-
sor of Col I producing ﬁbroblasts and myoﬁbroblasts in the liver
(Atzori et al., 2009). Despite these studies, overall understand-
ing of the origin and differentiation pathways of Col I producing
ﬁbroblasts and myoﬁbroblasts remains poor. Identiﬁcation of the
major developmental pathway of these cells will be an essential step
toward the development of therapeutic interventions for organ
ﬁbrosis.
CHALLENGING THE EMT HYPOTHESIS
Epithelial–mesenchymal transition is a process that was origi-
nally characterized in the context of embryonic development,
in which epithelial cells lose their original phenotypic and func-
tional features, including cell–cell adhesion and cell polarity, while
acquiring migratory and invasive properties (Thiery et al., 2009).
In vitro cell culture studies have shown clearly and reproducibly
that transforming growth factor-β (TGFβ) treatment of epithelial
cells induces expression of mesenchymal markers and morphol-
ogy with a concomitant loss of epithelial markers (Qi et al., 2005;
Venkov et al., 2007). Over the past 15 years, numerous studies have
proposed that EMTalso contributes to the activatedﬁbroblast pool
in various regenerative and pathogenic processes. For example,
transition from epithelial tumor cells to mesenchymal cells occurs
at the invasive front of many tumors, driving tumor progres-
sion and metastasis. In addition, inﬂammation-induced epithelial
cell damage in parenchymal organs such as the liver, lungs, and
kidneys recapitulates part of the EMT process in that epithelial
cells acquiremesenchymal cell-like properties andmigrate beyond
the basal membrane to the interstitium, where they differentiate
into Col I producing ﬁbroblasts and myoﬁbroblasts. However, the
inﬂammation-associated EMT hypothesis has been challenged by
an increasing number of studies, and lacks convincing evidence
(Wells, 2010; Kriz et al., 2011).
For example, the EMT hypothesis for kidney ﬁbrosis was ﬁrst
reported by Strutz et al. (1995), when the authors used FSP-1
(ﬁbroblast speciﬁc protein-1/S100A4) as a marker of mesenchy-
mal lineage. However, subsequent characterization revealed that
FSP-1 is not a mesenchymal cell speciﬁc marker, and is expressed
on leukocytes and endothelial cells as well. Similarly, expression
of vimentin, another marker commonly used in EMT studies, is
not enough on its own to identify mesenchymal cells, because
a subset of epithelial cells express vimentin in both resting and
inﬂammatory-states (Grone et al., 1987; Witzgall et al., 1994).
Moreover, recent extensive andwell designed cell-fate tracing stud-
ies have not provided any evidence for inﬂammation-associated
EMT (Humphreys et al., 2010; Scholten et al., 2010). Unless the
inﬂammation-induced conversion of epithelial cells intoCol I pro-
ducing ﬁbroblasts andmyoﬁbroblasts in vivo can be demonstrated
more convincingly, the role of EMT in organ ﬁbrosis should be
reconsidered.
FIBROCYTES MAKE ONLY A MINIMAL CONTRIBUTION TO
ORGAN FIBROSIS
The existence of bone marrow-derived ﬁbrocytes was originally
reported by Bucala et al. (1994). Later, Strieter and colleagues
reported that ﬁbrocytes express several chemokine receptors and
are recruited to inﬂamed tissues in a CXCR4 dependent manner,
where they contribute to the Col I producing myoﬁbroblast pool
after bleomycin-induced epithelial injury in the lungs (Phillips
et al., 2004). We have also demonstrated that blocking chemokine
receptors CCR1, 2, 5, and 7 in mouse lung or kidney ﬁbrosis mod-
els reduces the number of myoﬁbroblasts detected and ameliorates
organ ﬁbrosis (Sakai et al., 2006; Ishida et al., 2007). However, it
remains unclear whether the cognate chemokines regulate organ
ﬁbrosis through the recruitment of ﬁbrocytes to the inﬂamed
tissues, by inﬂuencing the activation or differentiation of ﬁbrob-
lasts, or through the recruitment of inﬂammatory cells such as
macrophages and neutrophils that subsequently inﬂuence the tis-
sue microenvironment. While many studies have conﬁrmed the
presence of ﬁbrocytes in ﬁbrotic disease, accumulating experi-
mental evidence suggests that the contribution of bone marrow-
derived cells to the Col I producing ﬁbroblast/myoﬁbroblast pool
is limited (Higashiyama et al., 2009, 2011).
ORIGIN OF CAPILLARY PERICYTES AND THEIR SIMILARITY
WITH TISSUE FIBROBLASTS
Recently, a novel role for pericytes as precursors of pro-ﬁbrotic Col
I producing cells has been described. Studies using Col 1α2–GFP
transgenic mice have demonstrated that CD73+PDGFRβ+ peri-
cytes/ﬁbroblasts migrate from capillaries to the interstitial space
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and differentiate to Col 1 producing myoﬁbroblasts in kidney and
liver ﬁbrosis models (Lin et al., 2008; Higashiyama et al., 2009).
In addition, Goritz et al. (2011) recently demonstrated that a spe-
ciﬁc pericyte subtype gives rise to scar-forming stromal cells in the
injured spinal cord. However, because ﬁbroblasts in the interstitial
space not only provide a scaffold formicro-tissue architecture such
as nephrons and renal tubules (in the case of the kidneys), but also
come into direct contact with microvessels, it is often difﬁcult to
distinguish between pericytes and tissue ﬁbroblasts under steady-
state conditions (Kriz et al., 2011). The similarities, differences,
and lineage relationship between pericytes and tissue ﬁbroblasts
remain to be elucidated.
THE ROLE OF INFLAMMATORY CELLS IN FIBROTIC TISSUE
Macrophage inﬁltration into inﬂamed tissues has been impli-
cated in chronic inﬂammation-induced organ ﬁbrosis (Wynn
and Barron, 2010). Inﬂamed tissue-inﬁltrating macrophages are
derived from CCR2+ inﬂammatory monocytes or CX3CR1hi res-
ident monocytes (Ricardo et al., 2008). The phenotype of these
macrophages is generally reported to match that of alternatively
activated cells (M2) rather than classically activated cells (M1).
M2 macrophages express immunosuppressive molecules such as
IL-10 and arginase I, which suppress the induction of Th1 cells
that produce the anti-ﬁbrotic cytokine IFNγ. On the other hand,
M1 macrophages express IL-1, IL-12, IL-23, and induce Th1 cell
inﬁltration and activation. However, it remains to be established
whether a particular macrophage subset with M2-type properties
preferentially inﬁltrates into ﬁbrotic tissues, or whether it is the
pro-ﬁbrotic microenvironment that drives macrophage polariza-
tion toward anM2phenotype. In addition to their roles in immune
regulation, macrophages play a pivotal role in matrix regression
during the recovery phase of ﬁbrosis (Dufﬁeld et al., 2005) and
in the regulation of stellate cell proliferation (Olaso et al., 2011).
In the future, conditional and lineage speciﬁc depletion or gene
targeting approaches may help to reveal the speciﬁc function and
overall role of each macrophage subset in tissue ﬁbrosis.
The contribution of T lymphocytes to organ ﬁbrosis seems
to be context dependent. While a number of studies suggest an
exacerbating role of T cells in ﬁbrosis, T cells also appear to
be dispensable because T cell-deﬁcient mice develop ﬁbrosis in
some models (Luzina et al., 2008). The general concept is that
prolonged inﬂammation induces a shift from a Th1 to Th2 phe-
notype, and the resulting production of Th2 cytokines induces
the inﬁltration of pro-ﬁbrotic eosinophils via cognate chemokine
(e.g., eotaxin) production. On the other hand, a role for recently
identiﬁed functional T cell subsets such as Th17 and regulatory
T cells in tissue ﬁbrosis has also begun to emerge. For exam-
ple, adoptive transfer of CD4 T cells restored bacterial-induced
lung inﬂammatory and ﬁbrotic responses in TCRβ deﬁcient mice
with an accompanying increase in lung IL-17A protein levels,
and IL-17 receptor α deﬁcient mice develop less severe inﬂam-
mation and ﬁbrosis than wild type counterparts (Simonian et al.,
2009). Recently,platelet-derived growth factor (PDGF)-producing
CD4+Foxp3+Tregs have been shown to promote lung ﬁbrosis by
activating ﬁbroblasts (Lo Re et al., 2011). A better understanding
of the roles that inﬂammatory cells play in the ﬁbrotic process
may reveal new points of therapeutic intervention, which may be
able to induce a shift from a pro-ﬁbrotic microenvironment to an
anti-ﬁbrotic microenvironment.
REGULATION OF FIBROSIS BY INFLAMMATORY MEDIATORS
The ﬁbrotic signaling cascade that occurs during chronic inﬂam-
mation, which is initiated by epithelial injury and results in
irreversible organ damage, is regulated by various inﬂammatory
mediators. The pro-ﬁbrotic roles of plasma components, platelet-
derived soluble factors, and cytokines produced by activated tissue
cells and inﬁltrating leukocytes, have been demonstrated in ani-
mal models. These mediators include factors induced as a part of
an inﬂammatory cascade, regulatory molecules that provide feed-
back during the inﬂammatory response, and factors constitutively
expressed in the body.
Transforming growth factor-β plays a central role in ﬁbrob-
last activation and ﬁbroblast-to-myoﬁbroblast differentiation, and
induces the expression of genes for ECM components including
Col 1. However, despite its great potential as a therapeutic target
for ﬁbrosis, inhibition of TGFβ signaling has unacceptable side
effects due to the critical role of this cytokine in the maintenance
of homeostasis (Leask, 2010).
Bonemorphogenic proteins (BMPs) belong to the TGFβ family
and regulate proliferation and differentiation of both mesenchy-
mal cells and epithelial cells (Rider and Mulloy, 2010). Recent
studies have revealed that BMP7 prevents ﬁbrosis by promoting
epithelial regeneration, while BMP antagonists such as gremlin
and ectodin drive organ ﬁbrosis by inhibiting BMP7 signaling.
Interestingly, there is a direct Smad-dependent counteraction of
the TGFβ pathway by BMP7 signaling, and vice versa (Zeisberg
et al., 2003).
G-protein coupled receptor ligands also regulate chronic
inﬂammation and the ﬁbrotic cascade. Angiotensin II (Ang II)
induces the expression of pro-ﬁbrotic factors such as connective
tissue growth factor (CTGF; Ruperez et al., 2003; Esteban et al.,
2004), and recent studies have revealed that there is an intracellular
cross-talk betweenAng II signaling and TGFβ signaling that coop-
eratively promotes ﬁbrosis (Campbell and Katwa, 1997; Schultz Jel
et al., 2002; Gao et al., 2009). Leukotrienes (LTs) not only induce
ﬁbroblast migration, proliferation, and matrix protein synthesis,
but also promote ﬁbrosis through the stimulation and activation
of TGFβ (Shim et al., 2006). On the contrary, prostaglandin E2
(PGE2), which has well established anti-inﬂammatory activities,
may suppress ﬁbrosis by inhibiting the proliferation, migration,
and differentiation of myoﬁbroblasts (Kohyama et al., 2001; Lama
et al., 2002;Thomas et al., 2007). Recent studies have demonstrated
that PGF2a receptor deﬁcientmice are resistant against bleomycin-
induced lung ﬁbrosis (Oga et al., 2009), and that LTB4 recep-
tor inhibitors and LPA1 inhibitors suppress bleomycin-induced
lung ﬁbrosis (Tager et al., 2008). Lysophosphatidic acid (LPA)
and sphingosine-1-phosphate (S1P) are liberated from stored
lipid precursors through enzymatic activation and provide migra-
tion, proliferation, and differentiation signals to a variety of cells
through the LPA receptors (LPA1–8) and S1P receptors (S1P1–5),
respectively (Pattanaik and Postlethwaite, 2010). LPA1 deﬁcient
mice are protected from bleomycin-induced lung ﬁbrosis and uni-
lateral ureteral ligation induced-renal ﬁbrosis (Tager et al., 2008).
The pro-ﬁbrotic role of LPA is reportedly mediated in part by
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the induction of ﬁbroblast-to-myoﬁbroblast differentiation (Yin
et al., 2008). S1P plays a critical role in the circulation of lympho-
cytes, and accordingly, inhibition of the S1P–S1P1 axis results in
strong immunosuppressive effects. In addition, S1P also regulates
themigration and activation of ﬁbroblasts, and recent studies have
revealed cross-talk between the S1P3 and TGFβ – Smad signaling
pathways that promote cardiac ﬁbrosis (Takuwa et al., 2010).
Plasma coagulation cascade proteases are also involved in ﬁbro-
sis (Chambers and Laurent, 2002); thrombin, factorVII, and factor
Xa activate protease-activated receptor-1 (PAR-1) on ﬁbroblasts
and induce their proliferation. In addition, these proteases pro-
mote ﬁbrosis through the induction of pro-ﬁbrotic molecules
such as platelet-derived growth factors and CTGF. CTGF medi-
ates mesenchymal stem cell (MSC)-to-ﬁbroblast differentiation as
well as ﬁbroblast activation (Ponticos et al., 2009; Lee et al., 2010),
while PDGFs induce the proliferation and activation of ﬁbroblasts
leading to vascular diseases and ﬁbrosis. Ijichi et al. (2011) have
demonstrated that CXC chemokines induce CTGF expression in
ﬁbroblasts, and that the inhibition of CXCR2 in tumor-bearing
mice impairs tumor progression.
Matrix metalloproteinases (MMPs) and their inhibitors, tis-
sue inhibitors of MMPs (TIMPs), play an important role in
the regulation of ECM turnover in ﬁbrotic tissues. While the
degradation of pathological ﬁbrillar collagen by MMPs is a key
event in the resolution of ﬁbrosis, the degradation of normal ECM
components in the early stages of ﬁbrosis promotes deposition of
newly synthesized collagen (Hemmann et al., 2007).
ATP released from damaged epithelial cells serves as a danger
signal to alert the immune system of tissue damage, and may also
trigger a ﬁbrotic cascade (Mortaz et al., 2010). Activation of the
Wnt/β-catenin signaling pathway, which regulates epithelial and
mesenchymal proliferation and activation, has been demonstrated
in lung epithelial cells of IPFpatients.Overall, this activationdrives
ﬁbrosis rather than epithelial repair, possibly due to cross-talk with
other pro-ﬁbrotic factors such asTGFβ andCTGF (Konigshoff and
Eickelberg, 2010). Furthermore, inhibition ofWnt signaling (Hen-
derson et al., 2010) and the BMP binding protein ectodin (Tanaka
et al., 2010) ameliorates renal ﬁbrosis. A better understanding of
the role of each inﬂammatory mediator in the ﬁbrotic cascade
is likely to reveal novel molecular targets for the early diagnosis,
prevention, and treatment of ﬁbrotic disease.
CONCLUSION AND FUTURE PERSPECTIVES
In recent years, confusion has surrounded the major source of
myoﬁbroblasts in ﬁbrosis, with attention centering on tissue-
resident ﬁbroblasts and pericytes (Figure 1). However, the relative
FIGURE 1 | Molecular and cellular mechanisms of chronic
inflammation-associated organ fibrosis. Organ ﬁbrosis is mediated
primarily by the induction of myoﬁbroblasts, which produce large amounts
of collagen I. Tissue ﬁbroblasts, transdifferentiated epithelial cells (EMT),
bone marrow-derived ﬁbrocytes, and pericytes have attracted interest as
potential myoﬁbroblast precursors. The ﬁbrotic cascade, from initial
epithelial damage to eventual myoﬁbroblast induction, is mediated by
complex biological processes such as macrophage inﬁltration, a shift from
Th1 toTh2 phenotype, and by inﬂammatory mediators such as
transforming growth factor-β.
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importance of the various developmental pathways of Col I pro-
ducing ﬁbroblasts and myoﬁbroblasts needs to be re-examined
by lineage tracing approaches, utilizing cell-type speciﬁc promot-
ers, and inducible systems in a range of ﬁbrosis models. It will
also be important to further elucidate the mechanisms underlying
the maintenance of myoﬁbroblasts during chronic inﬂammation.
It is possible that precursor cells provide a continuous supply of
myoﬁbroblasts, that myoﬁbroblasts have proliferative potential, or
that the myoﬁbroblast lifespan is relatively long. A deeper under-
standing of the population dynamics of myoﬁbroblasts and their
precursors may reveal new points of therapeutic intervention with
the potential to halt myoﬁbroblast accumulation in ﬁbrotic tissue.
Although removal of the cause of chronic inﬂammation is
essential and effective for the prevention and treatment of tis-
sue ﬁbrosis (for example, virus clearance by interferon effectively
prevents viral hepatitis-associated ﬁbrosis), this can be challenging
as the precise cause of the inﬂammation is oftenunclear.Given that
in most cases steroids are largely ineffective against ﬁbrosis, cur-
rently there is no effective drug available for patients with clinically
signiﬁcant organﬁbrosis. Further elucidation of themolecular and
cellular bases for chronic inﬂammation-associated organﬁbrosis is
imperative for the development of effective anti-ﬁbrotic therapies.
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